Mallinckrodt and Novoteris Receive Clearance from Health Canada to St art Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications

— Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 — STAINES-UPON-THAMES, United Kingdom and GARDEN GROVE, CA – April 1, 2020 — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Novoteris, LLC, a clinical stage medical device and pharmaceutical developer focused on innovative nitric